Aclarion, Inc. (NASDAQ:ACON) Sees Significant Drop in Short Interest

Aclarion, Inc. (NASDAQ:ACON) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 31,021 shares, a decrease of 26.6% from the December 15th total of 42,256 shares. Approximately 4.7% of the shares of the stock are sold short. Based on an average daily volume of 105,445 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 105,445 shares, the short-interest ratio is currently 0.3 days. Approximately 4.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, October 8th. Wall Street Zen raised shares of Aclarion to a “hold” rating in a research note on Saturday, December 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Aclarion has a consensus rating of “Sell”.

Aclarion Stock Down 5.3%

Aclarion stock opened at $3.79 on Monday. The business’s 50-day simple moving average is $5.86 and its 200 day simple moving average is $6.98. The stock has a market cap of $3.22 million, a price-to-earnings ratio of -0.25 and a beta of 1.44. Aclarion has a 12-month low of $3.68 and a 12-month high of $692.85.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.64) by ($0.29). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. As a group, sell-side analysts expect that Aclarion will post -263.33 EPS for the current year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.